A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
Shares of Poseida Therapeutics Inc.
PSTX,
+1.22%
were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd.
4502,
-0.12%
to study and commercialize up to eight…
